FCGR1A — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL13917176	1.00	1/20
SCHEMBL13421296	0.96	1/20
SCHEMBL13917185	0.89	1/20
SCHEMBL13921798	0.84	1/20
SCHEMBL13420987	0.82	1/20
SCHEMBL13420936	0.82	1/20
SCHEMBL13421092	0.81	1/20
SCHEMBL13917179	0.81	1/20
SCHEMBL13421360	0.81	1/20
SCHEMBL13421062	0.80	1/20
SCHEMBL13917183	0.80	1/20
SCHEMBL13917186	0.80	1/20
SCHEMBL13917188	0.80	1/20
SCHEMBL3200004	0.80	1/20
SCHEMBL13921832	0.80	1/20
SCHEMBL13420995	0.79	1/20
SCHEMBL13921837	0.78	1/20
SCHEMBL13421038	0.78	1/20
SCHEMBL13921814	0.77	1/20
SCHEMBL13421029	0.77	1/20

Clinical trials — most relevant to FCGR1A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of Allergen Immunotherapy on Anti-viral Immunity in Patients With Allergic Asthma	PHASE4	COMPLETED
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)	PHASE4	COMPLETED
Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients	PHASE2/PHASE3	COMPLETED
Allergic Rhinitis, Immunotherapy and Vitamin d	PHASE2/PHASE3	UNKNOWN
Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations	PHASE2	NOT_YET_RECRUITING
Effect of Anti-IgE in Chronic Urticaria	PHASE2	COMPLETED
Safety and Efficacy Study of VIS649 for IgA Nephropathy	PHASE2	COMPLETED
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment	PHASE2	UNKNOWN
Post IVIG Medication in Children With Immune Thrombocytopenia	PHASE1	UNKNOWN
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma	PHASE1	ACTIVE_NOT_RECRUITING
Preventive IVIG Therapy for Congenital Heart Block	EARLY_PHASE1	COMPLETED
Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.	nan	RECRUITING
Prognostic Value of CD64 Marker for Patients in Intensive Care Unit	nan	UNKNOWN
Role of the Neonatal Fc Receptor for IgG in the Pathophysiology of Lupus	nan	COMPLETED
Subclass of Donor-specific Antibody as a Risk Factor of Antibody Mediated Rejection in Renal Transplantation	nan	COMPLETED
Study if the Presence of Functional FcERI/RII on the Surface of Human Blood Platelet	nan	UNKNOWN
Comparison Between Methyl Prednisolone and Intravenous Dexamethazone in Severe Immune Thrombocytopenic Purpra	nan	UNKNOWN
Kinetics of Nasal Cytokine Responses to Mechanical Stimulation	nan	COMPLETED
Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer	nan	RECRUITING
FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver Transplantation	nan	UNKNOWN
Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases?	nan	UNKNOWN
Contribution of Nasal IgE Production to the Boost of Systemic Allergen-specific IgE Upon Nasal Allergen Contact	nan	RECRUITING
sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN	nan	UNKNOWN
Correlation Between IgE Parameters and the Response to Omalizumab in Subjects With Severe Asthma	nan	WITHDRAWN
The Effect of Omalizumab on Responses to Cat Allergen Challenge	nan	COMPLETED
Studying Blood and DNA Samples From Patients With Breast Cancer Treated With Chemotherapy With or Without Trastuzumab	nan	COMPLETED
Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy	nan	COMPLETED
Study of Neonatal IgG Fc Receptor Expression in Natural Killer T Cells Expressing an Invariant T Receptor : Implication in the Pathophysiology of Systemic Lupus	nan	RECRUITING
Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases	nan	RECRUITING
Obinutuzumab in the Management of Idiopathic Membranous Nephropathy	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a FCGR1A binder may also engage these)

Protein	Name	Similarity
Q92637	—	0.994	Q92637 →
P26151	—	0.992	P26151 →
E2RP87	—	0.992	E2RP87 →
P08637	—	0.991	P08637 →
Q68SN8	—	0.991	Q68SN8 →
Q09TM2	—	0.991	Q09TM2 →
Q8SPW2	—	0.991	Q8SPW2 →
Q9N2I5	—	0.990	Q9N2I5 →
A3RFZ7	—	0.990	A3RFZ7 →
Q09TM4	—	0.990	Q09TM4 →
P79107	—	0.988	P79107 →
H0VDZ8	—	0.987	H0VDZ8 →
P27645	—	0.987	P27645 →
M3XWH1	—	0.987	M3XWH1 →
FCGR3B	Low affinity immunoglobulin gamma Fc region receptor III-B	0.986	landscape →
A0A0B4J1G0	—	0.986	A0A0B4J1G0 →
Q60513	—	0.985	Q60513 →
Q6DN72	—	0.985	Q6DN72 →
Q3B8P2	—	0.985	Q3B8P2 →
Q28942	—	0.984	Q28942 →
B6A8R8	—	0.984	B6A8R8 →
Q8SPV8	—	0.984	Q8SPV8 →
Q63203	—	0.984	Q63203 →
B6A8C7	—	0.984	B6A8C7 →
P08508	—	0.984	P08508 →
Q6XPU4	—	0.983	Q6XPU4 →
P08101	—	0.983	P08101 →
P0DTI4	—	0.982	P0DTI4 →
Q5NKV2	—	0.982	Q5NKV2 →
Q14953	—	0.982	Q14953 →